Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report
Abstract Drug‐related pneumonitis (DRP) caused by epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) is a fatal adverse event in patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). The diagnosis of DRP is based on radiological findings, the temporal association of pr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15250 |
| Summary: | Abstract Drug‐related pneumonitis (DRP) caused by epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) is a fatal adverse event in patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). The diagnosis of DRP is based on radiological findings, the temporal association of presentation with the initiation of a systemic therapeutic agent, and the exclusion of other likely causes. Here we report a case in which severe adenoviral pneumonia mimicking DRP occurred during treatment with osimertinib, and osimertinib was successfully resumed after recovery from adenoviral pneumonia. |
|---|---|
| ISSN: | 1759-7706 1759-7714 |